Wnt family member 10AGenealiases: ECTD16 · OODD · SSPS · STHAG4
Q-omics provides the consensus-scored WNT10A profile across patient tissues and cancer cell-line models. WNT10A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, WNT10A is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, WNT10A RNA expression shows 13,446 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KICH, and TGCT as cancer lineages where WNT10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT10A survival associations across molecular data types. WNT10A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT10A RNA expression–survival associations across cancer types. High WNT10A expression shows unfavorable associations in KIRP, LUSC, UVM and PAAD, but favorable associations in UCS and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for WNT10A RNA expression.
This table summarizes WNT10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for WNT10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT10A shows lower tumor expression in KICH, KIRC and BRCA and higher tumor expression in THCA, LUAD and HNSC. The KICH box plot shows higher WNT10A RNA expression in normal versus tumor tissue (log2 FC = −2.903, t-test p < 0.001).
This table shows molecular features associated with WNT10A in patient tissues and cancer cell lines. In patient samples, WNT10A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and OVARY.
